Jura Health Welcomed by Colorado Medicaid as an Approved Provider for Testing for Suspected Rare Diseases
June 20 2024 - 11:55AM
Jura Health, an Innosphere Ventures client company, committed to
health equity for rare disease patients and their families, is
pleased to announce that its offerings are now approved for payment
by Medicaid in Colorado. This new coverage will enhance access to
crucial health information for anyone suspected of having a rare
disease.
Jura Health’s Emerge™ Platform provides whole genome sequencing
(WGS), genetic counseling, and next step support; providing a
personalized plan for individuals facing the complexities of rare
genetic disorders. The average time to a diagnosis for a rare
disease patient is 5 years. Jura Health aims to reduce that to 1
month. This Medicaid expansion ensures that more people in Colorado
can access essential diagnostic and support services that can
significantly improve their care journey.
“We are thrilled to have Medicaid approval in Colorado,” said
Chris Moore, CEO of Jura Health. “This milestone is a first step
toward our goal of making advanced genetic testing and counseling
available across the country, especially to those in underserved
communities. Early and accurate diagnosis can change the trajectory
of a patient’s journey with a rare disease and now more families
can benefit from our services without the burden of financial
barriers.”
Whole genome sequencing is a powerful tool that can identify
genetic mutations responsible for rare diseases, often leading to
earlier diagnosis and targeted treatment plans. Jura Health’s
Emerge Platform provides access to WGS, on-demand multilingual
genetic counseling services and personalized next steps that
provide patients and their families with critical information and
emotional support, helping them navigate the complexities of a rare
disease diagnosis. Additionally, Jura Health’s advocacy support
assists patients and their families in connecting with resources,
support networks, and treatment options.
The impact of rare diseases is profound, affecting approximately
30 million Americans. Nationally, Medicaid covers 43% of births and
17.8% of all Americans. Obtaining Medicaid approval in Colorado is
a significant first step towards bridging the gap in healthcare
disparities, offering hope and tangible support to those who need
it most.
“Access to genetic testing and counseling should be a
fundamental aspect of healthcare, not a privilege,” said Andrea
Girman, MD, MPH, Head of Patient and Provider Advocacy at Jura
Health. “This development is a game-changer for patients suspected
of having a rare disease. It brings us closer to our vision of a
healthcare system where every individual, regardless of their
financial situation or where they live, can receive the care and
support they deserve.”
For more information about Jura Health, please visit
www.jura.health.
Laurel Burk
Jura Health
720-414-8990
Laurel.Burk@Jura.Health